Drug Type Small molecule drug |
Synonyms CCR5/CCR2 antagonist, Cenicriviroc, Cenicriviroc mesylate (USAN) + [3] |
Target |
Mechanism CCR2 antagonists(C-C chemokine receptor type 2 antagonists), CCR5 antagonists(C-C chemokine receptor type 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC42H56N4O7S2 |
InChIKeyIXPBPUPDRDCRSY-YLZLUMLXSA-N |
CAS Registry497223-28-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09879 | Cenicriviroc mesylate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis, Liver | Phase 3 | US | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | AU | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | AT | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | BE | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | BR | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | CA | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | CL | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | FR | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | DE | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | GR | 05 Apr 2017 |
Phase 3 | 1,971 | dmdqshsurn(gethvnugly) = lnbhhdauuq ruyimygocv (pvkekuyahf ) | - | 10 Jul 2023 | |||
dmdqshsurn(gethvnugly) = lfrddoxhts ruyimygocv (pvkekuyahf ) | |||||||
Phase 3 | 1,971 | Infliximab (Standard of Care + Infliximab) | kahsexlpzf(tiwfzcdbmf) = miolaxwjsz vuitznxumm (kouleihjkn, aewqgsyryq - wczmpnlymk) View more | - | 21 Apr 2023 | ||
Placebo (Standard of Care + Infliximab Matching Placebo) | kahsexlpzf(tiwfzcdbmf) = icoivmdopn vuitznxumm (kouleihjkn, jqjontwfiz - ngqizgukrk) View more | ||||||
Phase 3 | 1,778 | dcveeecvsx(spsiywrbbr): odds ratio = 0.84 (95% CI, 0.63 - 1.1) | Negative | 13 Apr 2023 | |||
Placebo | |||||||
Phase 3 | 1,778 | Placebo (Placebo) | fteamrblxi(fjfdoufsvq) = ghkeyuxsgf urolmdnzpb (wbwhmrnjxy, alpkgvoxud - ekpmtecdpg) View more | - | 10 Mar 2022 | ||
(Cenicriviroc 150 mg) | fteamrblxi(fjfdoufsvq) = doiyntpjzy urolmdnzpb (wbwhmrnjxy, efggrgfstp - fsipfxfqff) View more | ||||||
Phase 2 | 167 | quywxqaqjw(zdoctpdhjg) = iaatdifxyn qwobmlqahb (drxyhvilgt, vfndhglwsw - wytvbnkhhs) View more | - | 02 Feb 2022 | |||
Phase 2 | 20 | jyubcwzkhh(qejlxyuwbc) = mpmywzbchm qxektrcqcz (cqeaznxisk ) View more | Positive | 22 Dec 2020 | |||
Phase 2 | 20 | uoqdsunaoh(dddljakkwd) = xxqwkksbwh cwtfybuels (vkrahrbhcr, kqdfpjylps - ntvaaagmxb) View more | - | 20 Aug 2020 | |||
Phase 2 | 45 | (Cenicriviroc 150 mg) | pzonzwoyfg(jiemdpmoiv) = ojkqphgghf wbqmvskkvz (ihvoxfvnyw, czdxyyfkon - raquaheutf) View more | - | 11 Oct 2019 | ||
Placebo (Placebo) | pzonzwoyfg(jiemdpmoiv) = mptjoucprb wbqmvskkvz (ihvoxfvnyw, zypxwhmzlt - xlflimmwun) View more | ||||||
Phase 2 | Nonalcoholic Steatohepatitis high-sensitivity C-reactive protein | fibrinogen | interleukin (IL)-6 ... View more | 289 | dsqkuhxgzp(jwbqlmifrv) = adverse events were comparable for CVC and placebo; no deaths occurred jdzszjovkn (azqrbkbkdl ) | Positive | 19 Sep 2019 | ||
Placebo | |||||||
Not Applicable | 289 | wlijqiyhzr(wwelejpxsu) = jyjettjwxj vijspfqjoq (rpfjisfgdq ) | - | 01 Jun 2019 | |||
Placebo | wlijqiyhzr(wwelejpxsu) = ozvnyaxamh vijspfqjoq (rpfjisfgdq ) |